Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
Silexion Therapeutics Corp reported a net loss of $2.7M for Q1 2026, with a loss per share of $0.85, compared to a net loss of $1.7M and $3.84 per share in Q1 2025. The increase in losses is attributed to heightened R&D spending for the clinical start of SIL204, with human studies anticipated in Q2 2026. The company has restored Nasdaq compliance and is utilizing public financings to support operations and clinical milestones.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments